Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2021-05-06 Earnings Release
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2021, reporting the company's financial and operating results for the quarter ended March 31, 2021. It specifically mentions that a press release announcing these results is furnished as Exhibit 99.1. The document itself is short (3607 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results, not a full interim report or annual report. The presence of a press release and the nature of the filing confirm this classification with high confidence.
2021-05-06 English
Proxy Solicitation & Information Statement 2021
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'SUPPLEMENT TO DEFINITIVE PROXY STATEMENT' and references a previously filed definitive proxy statement on Schedule 14A related to the Annual Meeting of Shareholders. It corrects the number of shares outstanding as of the record date but does not change the proposals or other substantive content of the proxy statement. The document is a supplement to the proxy materials, which are used to solicit shareholder votes. The presence of Schedule 14A and the nature of the content clearly indicate this is related to proxy solicitation materials. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 4126 characters, which is consistent with a supplement rather than a full report or announcement. Hence, the classification is PSI with high confidence.
2021-05-03 English
Remuneration Information 2021
Remuneration Information Classification · 100% confidence The document is titled 'DEFA14A' and references 'Schedule 14A (Rule 14a-101)' which is the SEC form for proxy statements. It includes phrases such as 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and 'Definitive Additional Materials.' The content includes detailed information about Regeneron Pharmaceuticals, including shareholder letters, business updates, and pipeline information, which are typical components of proxy statements. The presence of 'Schedule 14A' and the proxy statement references clearly indicate this is a proxy solicitation or related materials. Therefore, the document fits the Remuneration Information category (DEF 14A), which covers reports detailing compensation and proxy materials for executives and directors.
2021-04-23 English
Proxy Solicitation & Information Statement 2021
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'SCHEDULE 14A' and is described as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It includes voting instructions for the Annual Meeting of Regeneron Pharmaceuticals, Inc., details on how to vote, and a list of proposals including election of directors and ratification of auditors. The document is clearly proxy solicitation material, providing information to shareholders to enable them to vote at the annual meeting. It is not the actual annual report, earnings release, or any other financial report. The document is definitive additional materials related to the proxy statement, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is 4416 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is PSI with high confidence.
2021-04-23 English
Proxy Solicitation & Information Statement 2021
Proxy Solicitation & Information Statement
2021-04-23 English
PRIMARY DOCUMENT
Director's Dealing
2021-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.